The purpose of this study is to investigate the safety and effectiveness of plamotamab
when it is given with tafasitamab and lenalidomide in participants with relapsed or
refractory DLBCL.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05328102.
Locations matching your search criteria
United States
Michigan
Ann Arbor
University of Michigan Rogel Cancer CenterStatus: Approved
Name Not Available
This is a randomized, multicenter, open-label, Phase 2 study of plamotamab combined with
tafasitamab plus lenalidomide versus tafasitamab plus lenalidomide in adult participants
with DLBCL who have relapsed after or are refractory to at least 1 prior line of therapy,
which must have included multi-agent chemoimmunotherapy inclusive of an anti-cluster of
differentiation (CD) 20 monoclonal antibody, and who are not candidates for autologous
stem-cell transplantation (ASCT), refuse ASCT, or relapse after ASCT.
The study was planned to be performed sequentially, with Part 1A (Safety run-in, with a
lower plamotamab dose), Part 1B (Safety run-in, with the target plamotamab dose) and Part
2 (Open-Label, randomized). The study was terminated by the Sponsor during Part 1A of the
study. No participants were enrolled in Part 1B or Part 2.
Lead OrganizationXencor, Inc.
